BIOTECanada applauds the Government of Canada for its continued progress through bilateral agreements with the provinces of Ontario, New Brunswick, Saskatchewan, Alberta, Newfoundland and Labrador, and British Columbia to improve access to drugs for rare diseases, advance early diagnosis, and screening. These collaborations mark significant milestones in advancing access to treatments for rare diseases, an effort BIOTECanada continues to champion. Ongoing investment to address the long-standing gaps in access to care is vital for patients in Canada with rare diseases to have greater access to life-changing treatments.
Timely access to transformative curative therapies—such as cell and gene therapies, biotechnologies, and drugs for rare diseases (DRDs)—requires the collaborative and transparent implementation of effective and sustainable policies designed to meet the needs of rare disease patients and the medicines available to address those needs.
To view the existing provincial bilateral agreements, visit: https://www.canada.ca/en/health-canada/corporate/transparency/health-agreements/shared-health-priorities/drugs-for-rare-diseases-bilateral-agreements.html